General Biotechnology, Guest content

Why the market does not like Flurizan

Guest content from Nicolaj H. Nielsen, managing director of Biostrat. A case-study on the recent licensing-deal between Myriad and Lundbeck: […]

Why the market does not like Flurizan Read Post »